Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: Pharmacokinetics and efficacy

American Journal of Transplantation

Volumn 13, Issue 8, 2013, Pages 2191-2197

  Min, S I ^a   Ha, J ^a   Kang, H G ^a   Ahn, S ^a   Park, T ^a   Park, D D ^a   Kim, S M ^a   Hong, H J ^a   Min, S K ^a   Ha, I S ^a   Kim, S J ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Conversion; pediatric kidney transplantation; pharmacokinetics; tacrolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TACROLIMUS;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT RECIPIENT; HEMATOCRIT; HUMAN; KIDNEY TRANSPLANTATION; MALE; MORNING DOSAGE; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL;

CONVERSION; PEDIATRIC KIDNEY TRANSPLANTATION; PHARMACOKINETICS; TACROLIMUS;

ADOLESCENT; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MEDICATION ADHERENCE; PROGNOSIS; PROSPECTIVE STUDIES; TACROLIMUS; TISSUE DISTRIBUTION;

EID: 84881372386     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12274     Document Type: Article

References (30)

1. Fine RN, Becker Y, De Geest S, et al. Nonadherence consensus conference summary report. Am J Transplant 2009; 9: 35-41.
2. Matas AJ, Humar A, Gillingham KJ, et al. Five preventable causes of kidney graft loss in the 1990s: A single-center analysis. Kidney Int 2002; 62: 704-714.
3. Weng FL, Israni AK, Joffe MM, et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 2005; 16: 1839-1848.
4. Dobbels F, Ruppar T, De Geest S, Decorte A, Van Damme-Lombaerts R, Fine RN., Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: A systematic review. Pediatr Transplant 2010; 14: 603-613.
5. Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC., Frequency and impact of nonadherence to immunosuppressants after renal transplantation: A systematic review. Transplantation 2004; 77: 769-776.
6. Bartosh SM, Ryckman FC, Shaddy R, Michaels MG, Platt JL, Sweet SC., A national conference to determine research priorities in pediatric solid organ transplantation. Pediatr Transplant 2008; 12: 153-166.
7. Hardinger KL, Park JM, Schnitzler MA, Koch MJ, Miller BW, Brennan DC., Pharmacokinetics of tacrolimus in kidney transplant recipients: Twice daily versus once daily dosing. Am J Transplant 2004; 4: 621-625.
8. Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: A randomized, open-label trial. Am J Transplant 2009; 9: 2505-2513.
9. 0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 2010; 90: 523-529.
10. Hougardy JM, Broeders N, Kianda M, et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation 2011; 91: 566-569.
11. Barraclough KA, Isbel NM, Johnson DW, Campbell SB, Staatz CE., Once- versus twice-daily tacrolimus: Are the formulations truly equivalent ? Drugs 2011; 71: 1561-1577.
12. Kramer BK, Charpentier B, Backman L, et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: A randomized phase III study. Am J Transplant 2010; 10: 2632-2643.
13. Heffron TG, Pescovitz MD, Florman S, et al. Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. Am J Transplant 2007; 7: 1609-1615.
14. Pape L, Heidotting N, Ahlenstiel T., Once-daily tacrolimus extended-release formulation: 1 year after conversion in stable pediatric kidney transplant recipients. Int J Nephrol 2011; 2011: 126251.
15. Zhao W, Fakhoury M, Baudouin V, et al. Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. Eur J Clin Pharmacol 2013; 69: 189-195.
16. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A., A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58: 259-263.
17. Ro H, Min SI, Yang J, et al. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit 2012; 34: 680-685.
18. Min SI, Kim SY, Ahn SH, et al. CYP3A5*1 allele: Impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. Transplantation 2010; 90: 1394-1400.
19. Chisholm MA, Lance CE, Williamson GM, Mulloy LL., Development and validation of an immunosuppressant therapy adherence barrier instrument. Nephrol Dial Transplant 2005; 20: 181-188.
20. Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 2005; 37: 867-870.
21. Wehland M, Bauer S, Brakemeier S, et al. Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenet Genomics 2011; 21: 179-184.
22. Canaparo R, Finnstrom N, Serpe L, et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin Exp Pharmacol Physiol 2007; 34: 1138-1144.
23. Glowacki F, Lionet A, Hammelin JP, et al. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. Clin Pharmacokinet 2011; 50: 451-459.
24. Niioka T, Satoh S, Kagaya H, et al. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. Transplantation 2012; 94: 1013-1019.
25. Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T., High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 2010; 25: 2757-2763.
26. Duijnhoven EM, Boots JM, Christiaans MH, Wolffenbuttel BH, Van Hooff JP., Influence of tacrolimus on glucose metabolism before and after renal transplantation: A prospective study. J Am Soc Nephrol 2001; 12: 583-588.
27. Uchida J, Kuwabara N, Machida Y, et al. Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: A short-term study on its effects on glucose metabolism. Transplant Proc 2012; 44: 128-133.
28. Mangray M, Vella JP., Hypertension after kidney transplant. Am J Kidney Dis 2011; 57: 331-341.
29. Wauters RP, Cosio FG, Suarez Fernandez ML, Kudva Y, Shah P, Torres VE., Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation. Transplantation 2012; 94: 377-382.
30. Degi A, Kerti A, Kis E, et al. Cardiovascular risk assessment in children following kidney transplantation. Pediatr Transplant 2012; 16: 564-576.